Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | PNP | P00491 | 2/20 | 0.44 |
| ▸ | TK1 | P04183 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | EDNRA | P25101 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HBB | P68871 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2057237 | 1.00 | ADORA3 (0.45) | ADORA3PNPTK1BLMUSP2 | |
| SCHEMBL16368459 | 0.92 | ADORA3 (0.43) | ADORA3PNPTK1BLMUSP2 | |
| SCHEMBL23171074 | 0.85 | ADORA3 (0.42) | ADORA3PNPTK1BLMUSP2 | |
| SCHEMBL29479236 | 0.85 | ADORA3 (0.47) | ADORA3PNPTK1BLMUSP2 | |
| SCHEMBL9116042 | 0.84 | ADORA3 (0.43) | ADORA3PNPTK1BLMUSP2 | |
| SCHEMBL3514475 | 0.84 | ADORA3 (0.48) | ADORA3PNPTK1BLMUSP2 | |
| SCHEMBL28899787 | 0.83 | ADORA3 (0.48) | ADORA3PNPTK1BLMUSP2 | |
| SCHEMBL3970963 | 0.83 | ADORA3 (0.48) | ADORA3PNPTK1BLMUSP2 | |
| SCHEMBL28384881 | 0.83 | ADORA3 (0.48) | ADORA3PNPTK1BLMUSP2 | |
| SCHEMBL13756819 | 0.83 | ADORA3 (0.48) | ADORA3PNPTK1BLMUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063659-A1 | Novel 2'-halomethylidene,2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives | MERRELL PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| US-20030109484-A1 | Novel 2'-halomethylidene, 2'-ethenylidene and 2'ethynyl cytidine, uridine and guanosine derivatives | MCCARTHY JAMES R (US) | 2003-06-12 | — | — | US | disclosed |
| US-5977325-A | NUCLEOSIDE DERIVATIVES USEFUL AS ANTICARCINOGENIC/ANTITUMOR AGENTS AND VIRICIDES | MERRELL PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | disclosed |
| US-5792841-A | ANTIVIRAL, ANTINEOPLASTIC AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1998-08-11 | — | — | US | disclosed |
| US-5616702-A | ANTITUMOR AGENTS, VIRICIDES | MERRELL PHARMACEUTICALS INC. (US) | 1997-04-01 | — | — | US | disclosed |
| US-5607925-A | Treatment of carcinoma by administration of 2'-halomethylidenyl-2'-deoxynucleosides | MERRELL PHARMACEUTICALS INC. (US) | 1997-03-04 | — | — | US | disclosed |
| US-5378693-A | Antitumor agents or viricides | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0372268-B1 | Novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives | MERRELL DOW PHARMA (US) | 1994-05-04 | — | — | EP | disclosed |
| CN-1022248-C | Novel 2'-halomethylidene, uridine and guanosine drivatives | MERRELL DOW PHARMA (US) | 1993-09-29 | — | — | CN | disclosed |
| EP-0372268-A1 | Novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-06-13 | — | — | EP | disclosed |
| CN-1042715-A | New 2 '-halogenated methylene, 2 '-vinylidene and 2 '-ethynyl cytidine, uridine and black glycoside derivates | MERRELL DOW PHARMA (US) | 1990-06-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063659-A1 | Novel 2'-halomethylidene,2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives | UMPS, NUDT14, NUDT1 | ADORA3 401/4885PNP 29/4885TK1 501/4885 |
| US-20030109484-A1 | Novel 2'-halomethylidene, 2'-ethenylidene and 2'ethynyl cytidine, uridine and guanosine derivatives | UMPS, NUDT1, NUDT14 | ADORA3 438/4885PNP 28/4885TK1 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.